scholarly journals Granular Cell Tumor of the Breast Coexisting with Ductal Carcinoma in situ: Case Report

2021 ◽  
pp. 303-308
Author(s):  
Yuko Ueki ◽  
Yoshiya Horimoto ◽  
Akihiko Shiraishi ◽  
Atsushi Arakawa ◽  
Hyonmi Sai ◽  
...  

Granular cell tumor (GCT) is a benign tumor arising from Schwann cells. GCT of the breast is rare and while predominantly benign, it can be difficult to differentiate from breast cancer by imaging. While it is not generally associated with breast cancer, we here report a rare case of GCT coexisting with ductal carcinoma in situ (DCIS). A 38-year-old Japanese woman had microcalcification suggestive of malignancy in the right upper breast and a 6-cm well-defined mass in the right lower breast. Ultrasonography showed that the lower mass was circular in shape with a clear border, and internal echo level was slightly uneven. Contrast-enhanced magnetic resonance imaging found that the inside was unevenly contrast-enhanced and showed fast/washout enhanced pattern. Hence, imaging could not exclude malignancy. Pathological diagnosis from biopsies taken from the upper calcification and lower mass was DCIS and GCT, respectively. Imaging showed no evidence of continuity between the two, but the patient elected for mastectomy. Final pathological diagnosis confirmed an S-100-positive and keratin-negative GCT for the lower lesion and no histological evidence of continuity. Although GCT is a rare disease, greater awareness of the disease and its imaging findings is needed to avoid overdiagnosis, particularly when it coexists with breast cancer.

2001 ◽  
Vol 51 (11) ◽  
pp. 879-882 ◽  
Author(s):  
Takuya Nojiri ◽  
Yasuki Unemura ◽  
Katsuyuki Hashimoto ◽  
Yoji Yamazaki ◽  
Masahiro Ikegami

2021 ◽  
Vol 28 (3) ◽  
pp. 329-332
Author(s):  
Mihai MEHEDINTU-IONESCU ◽  
◽  
Stefan-Andrei COMAN ◽  
Horia-Alexandru TOADER ◽  
◽  
...  

The following article represents a clinical case study of a synchronous breast cancer in a 47 year old woman with no prior significant comorbidities.Up to 10% of all breast cancers can be synchronous (usually found with the help of breast MRI). The occurrence of bilaterally is considerable with invasive lobular carcinoma. The patient observed after self-palpating her breast a nodule in the infero-external quadrant of the right breast. During almost 4 months the patient underwent punch biopsy of the right breast, lumpectomy and finally double mastectomy with immediate reconstruction using Mentor implants and AMD. The histopathological result showed ductal carcinoma in situ in the right breast and lobular carcinoma in situ in both breasts. Postoperatively the patient is free of cancer, but under clinical and imagistic surveillance.


2002 ◽  
Vol 126 (6) ◽  
pp. 731-733 ◽  
Author(s):  
Hikmat Al-Ahmadie ◽  
Per-Olof Hasselgren ◽  
Rawia Yassin ◽  
George Mutema

Abstract A 57-year-old woman presented with a 2-year history of a palpable mass in the upper inner quadrant of the right breast. A 1.1-cm, poorly circumscribed, firm tumor nodule was noted, consisting of 2 histologically distinct lesions in the same location, with some areas showing purely well-differentiated invasive ductal carcinoma and others composed of granular cell tumor. In 1 area, the 2 tumors collided and infiltrated each other. The invasive ductal carcinoma was admixed with ductal carcinoma in situ of solid and cribriform types. To our knowledge, this is the first case report demonstrating colocalization of these 2 neoplasms, which raises questions regarding causal relationship. We also review the literature on granular cell tumor of the breast.


2018 ◽  
Vol 23 (4) ◽  
pp. 237-248 ◽  
Author(s):  
Hugo Villanueva ◽  
Sandra Grimm ◽  
Sagar Dhamne ◽  
Kimal Rajapakshe ◽  
Adriana Visbal ◽  
...  

Abstract Ductal carcinoma in situ (DCIS) is a non-obligate precursor to most types of invasive breast cancer (IBC). Although it is estimated only one third of untreated patients with DCIS will progress to IBC, standard of care for treatment is surgery and radiation. This therapeutic approach combined with a lack of reliable biomarker panels to predict DCIS progression is a major clinical problem. DCIS shares the same molecular subtypes as IBC including estrogen receptor (ER) and progesterone receptor (PR) positive luminal subtypes, which encompass the majority (60–70%) of DCIS. Compared to the established roles of ER and PR in luminal IBC, much less is known about the roles and mechanism of action of estrogen (E2) and progesterone (P4) and their cognate receptors in the development and progression of DCIS. This is an underexplored area of research due in part to a paucity of suitable experimental models of ER+/PR + DCIS. This review summarizes information from clinical and observational studies on steroid hormones as breast cancer risk factors and ER and PR as biomarkers in DCIS. Lastly, we discuss emerging experimental models of ER+/PR+ DCIS.


PLoS ONE ◽  
2016 ◽  
Vol 11 (9) ◽  
pp. e0160835
Author(s):  
Hoe Suk Kim ◽  
Minji Jung ◽  
Sul Ki Choi ◽  
Woo Kyung Moon ◽  
Seung Ja Kim

Sign in / Sign up

Export Citation Format

Share Document